Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

Peter Connick, Siddharthan Chandran, Madhan Kolappan et al.|The Lancet Neurology|2012

Cited by 606